“…Similarly to other clinical studies, the occurrence of schizophrenia-like symptoms [ 18 , 19 , 20 , 21 , 22 , 23 ]—as well as numerous biochemical and morphological alterations, reminiscent of those observed in patients—have been described in experimental animals [ 24 , 25 , 26 , 27 , 28 ], in which the GSH deficit was induced by genetic manipulation in genes encoding GCL enzyme [ 29 , 30 , 31 ], or by specific compounds that reduce GSH concentration [ 32 , 33 ]. In our recently published study (Górny et al [ 34 ]), the chronic administration of l -buthionine-(S,R)-sulfoximine (BSO), a specific GCL inhibitor, to newborn male Sprague-Dawley rats between the postnatal day p5 and p16, has been shown to induce the tissue-dependent decreases in GSH contents, paralleled by alterations in homeostasis of sulfur-containing amino acids (Met and Cys), when measured 4 h after the last dose. As a consequence of the changes in the contents of these thiols in peripheral tissues (liver, kidneys), and in certain brain structures (prefrontal cortex, PFC; hippocampus, HIP) during early postnatal development, schizophrenia-like behaviors appeared in adulthood (p90–p93), which were accompanied by changes in the global DNA methylation status in the studied brain structures [ 34 ].…”